Archive

Weekly Round UpWeekly Round Up
Telehealth Is Booming. Here’s What Comes Next.

Telehealth Is Booming. Here’s What Comes Next.

Telehealth’s trillion-dollar trajectory, 2026 tech budget priorities, and the engagement gap reshaping virtual care.

Long Form ArticleLong Form Article
Telehealth’s Next Phase: Scale, Integration, and Value Creation

Telehealth’s Next Phase: Scale, Integration, and Value Creation

A data-driven analysis of market growth, regional dynamics, and end-use economics shaping virtual care through 2035

Weekly Round UpWeekly Round Up
GLP-1s Go Prime Time, Sub-$50M M&A Rebounds, and 67% Back Specialty Care

GLP-1s Go Prime Time, Sub-$50M M&A Rebounds, and 67% Back Specialty Care

Pharma pushes weight-loss drugs to the mass market and small deals clear 4 in 60 days, while India’s patient satisfaction drops to 46%.

Long Form ArticleLong Form Article
Where Healthcare M&A Is Most Likely to Hold Up in 2026

Where Healthcare M&A Is Most Likely to Hold Up in 2026

Healthcare dealmaking may be slower and more selective, but it’s far from stalled.

Weekly Round UpWeekly Round Up
Who’s Winning in Healthcare Now: AI Megadeals, Staffing Giants & Telehealth Choices

Who’s Winning in Healthcare Now: AI Megadeals, Staffing Giants & Telehealth Choices

Deal count surges in healthcare AI and compliance tightens on staffing, while reliability drives 66% of telehealth platform decisions.

Long Form ArticleLong Form Article
AI Is Outgrowing the Mega-Deal

AI Is Outgrowing the Mega-Deal

For years, healthcare AI funding followed a familiar arc: bigger rounds, fewer companies, and a steady march toward “mega-deals.” In 2025, that narrative is starting to bend.

Weekly Round UpWeekly Round Up
AstraZeneca’s $15B Bet, €4bn Pharma Exit, and 36% Skip Care

AstraZeneca’s $15B Bet, €4bn Pharma Exit, and 36% Skip Care

AstraZeneca commits $15B to China and Permira eyes a €4bn sale of Neuraxpharm, while high costs force 36% of rural U.S. patients to forgo treatment.

Weekly Round UpWeekly Round Up
$9.9M HIPAA Fines, 50% Integration Pain, 78% Betting On AI

$9.9M HIPAA Fines, 50% Integration Pain, 78% Betting On AI

78% of leaders turn to AI for efficiency and $9.9M in HIPAA fines signals tougher enforcement, while integration complexity stalls virtual care for 50%.

Long Form ArticleLong Form Article
Cost Containment in 2026: Pharma’s AI-Powered Reset

Cost Containment in 2026: Pharma’s AI-Powered Reset

Facing tighter margins and rising R&D costs, life sciences executives are prioritizing cost discipline like never before.

Weekly Round UpWeekly Round Up
Healthcare M&A Under Pressure, Gavi Funding at Risk, and the Rise of Personalized Medicine

Healthcare M&A Under Pressure, Gavi Funding at Risk, and the Rise of Personalized Medicine

The U.S. conditions Gavi funding on thimerosal elimination and North America holds 45% of the personalized medicine market, while integration risk tops M&A concerns.

Long Form ArticleLong Form Article
What Will Really Slow Healthcare M&A in the Next 12 Months?

What Will Really Slow Healthcare M&A in the Next 12 Months?

Healthcare dealmaking isn’t short on capital—or targets. What it is short on is certainty.

Weekly Round UpWeekly Round Up
Healthcare’s New Reality: $191B Deals, 61% More M&A, Rising Scrutiny

Healthcare’s New Reality: $191B Deals, 61% More M&A, Rising Scrutiny

Digital health funding rebounds 35% and 74% cite innovation as the top cost driver, while regulators target pharmacy supply chains.

FirstBack
12345678
Next Last